ABSTRACT
This chapter examines huge financing needs of the start-up, throughout its life cycle, which are presently and conservatively estimated to be over $800 million. The financing life cycle of a biotechnology start-up includes several steps that can be distinguished to belong in one of four major stages, namely, seed, early stage, expansion stage, and late stage. In bridge financing, Advanced Therapies (AT) has reached a target pool of three molecular candidates that are planned to enter the arduous phase of clinical research within a year. Royalty financing is an alternative financing method to either equity financing or out-licensing. Borrowing money from a willing financial institution is another financing option for biopharmas. Moving along the AT’s financing life cycle, its young entrepreneurs may be faced with the start of a large preclinical testing phase. In bridge financing, AT has reached a target pool of three molecular candidates that are planned to enter the arduous phase of clinical research within a year.
